GlassScriptPhysician profile
Thomas Casimir Krol
NPI 1568431146
$8,769.05
in general payments reported to CMS, 2019-2025
32 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $283 · 2021: $1,128 · 2022: $2,078 · 2023: $2,158 · 2024: $1,478 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.59 |
| Education | $112.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,833.41 | 2019-2024 | |
| Janssen Biotech, INC. | $1,188.09 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $991.75 | 2019-2024 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.96 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $431.97 | 2019-2025 | |
| Gilead Sciences, INC. | $335.79 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $315.84 | 2019-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $305.31 | 2019-2024 | Dificid, Pifeltro |
| Celgene Corporation | $226.05 | 2021-2023 | Zeposia |
| Genzyme Corporation | $194.56 | 2022-2024 | |
| Allergan, INC. | $164.64 | 2019 | |
| Ferring Pharmaceuticals INC. | $164.15 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $158.96 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $138.80 | 2019-2022 | |
| Lilly USA, LLC | $111.61 | 2024 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $97.27 | 2021-2024 | Hadlima, Renflexis |
| Enterra Medical, INC. | $93.86 | 2022-2023 | |
| Amgen INC. | $89.88 | 2021 | |
| Phathom Pharmaceuticals, INC. | $61.71 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $52.87 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $50.82 | 2019 | |
| Ironwood Pharmaceuticals, INC | $38.20 | 2020-2022 | |
| Redhill Biopharma INC. | $32.66 | 2020-2021 | |
| Ardelyx, INC. | $25.22 | 2023 | Ibsrela |
| Alfasigma USA, INC. | $22.40 | 2020 | |
| Ucb, INC. | $22.17 | 2020 | |
| Pinnacle Biologics, INC | $18.82 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.45 | 2023 | Cyltezo |
| Celltrion USA INC. | $13.22 | 2024 | Zymfentra |
| Shionogi INC | $12.36 | 2019 | |
| Intra-Sana Laboratories | $7.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Krol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.